Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

BHVN Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Cash & Equivalents	248.4	240.09	76.06	82.51
Short-Term Investments	133.42	260.46	0	0
Cash & Cash Equivalents	381.82	500.55	76.06	82.51
Cash Growth	-23.72%	558.13%	-7.82%	-
Other Current Assets	60.63	86.42	18.77	7.25
Total Current Assets	442.45	586.97	94.82	89.76
Property, Plant & Equipment	17.19	17.51	13.01	7.58
Long-Term Investments	0	0	0	1.18
Goodwill and Intangibles	19.79	19.79	19.79	0
Other Long-Term Assets	33.79	37.51	14.44	12.99
Total Long-Term Assets	70.77	74.82	47.24	21.74
Total Assets	513.21	661.78	142.06	111.5
Accounts Payable	15.58	45.92	4.78	2.76
Other Current Liabilities	39.85	44.11	37.16	27.12
Total Current Liabilities	55.42	90.02	41.94	29.88
Long-Term Debt	27.57	30.58	2.8	0
Other Long-Term Liabilities	2.25	2.41	2.64	4.84
Total Long-Term Liabilities	29.81	32.99	5.44	4.84
Total Liabilities	85.24	123.01	47.37	34.72
Total Debt	27.57	30.58	2.8	0
Debt Growth	-9.85%	993.35%	-	-
Retained Earnings	-499.29	-91.12	0	-
Comprehensive Income	-0.07	0.28	0	0
Shareholders' Equity	427.98	538.77	34.69	16.78
Net Cash / Debt	354.25	469.97	73.26	82.51
Net Cash / Debt Growth	-24.62%	541.51%	-11.21%	-
Net Cash Per Share	4.98	10.50	1.86	2.10
Working Capital	387.02	496.95	52.89	59.88
Book Value Per Share	6.01	12.04	0.88	0.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).